Replies to post #545643 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

That doesn't say what you say elsewhere it says it says. This is more of the same false information. You pointed and quoted something that has nothing to do with what you said previously and what I called you out on, and you did it as if you were proving me wrong. You need to go back and figure out what you're actually trying to say here. No one is questioning the crossover. We all know that happened.

There is no issue about "single dose" or "double dose". Your previous post was deeply confused. Your answer is not on point.

This is what I called you out on:

The DCVax-L treatment arm used a crossover dosing when patients were diagnosed as recurring GBM (progression). 90% of the treatment arm had crossover (2nd dose) during the trial. That is the double dosing. It is in the SAP document.

The external comparator trials were not screened for dosing and most were single dosed. Thus DCVax-L had two doses, most comparator trials used single dose. That is confounding the trial results. NWBO statisticians statistically manipulated the OS endpoint data to try to compensate for the confounding of the data. That was their attempt to make it acceptable for regulators. FDA not likely to buy it.

[Goats'nCrows]

"90%...were double dosed." With grapefruit juice? A treatment lacking efficacy? Or it's just so confounded, gosh darn it, they'll never know nothing?

[Roman516]

NWBO's explanation to you, IMPO.
The OS data stands as is, "OS DATA GOLDEN"
Ditch the PFS statistical guess based on the OS results.
Fact is that DCVax-L works.
Fact is that DCVax-L added with other compounds improves overall performance and provides additional extended life results.
Dr. Linda Liau's early initial indications, 50% survival after 100 months.
NWBO has a path forward and that is a fact worthy for RA approvals, IMPO.
The latest version of the Flaskworks device has been tested and should be used
to increase the probability for higher vaccine production rates, 10x over standard
processes. Advanced automation capability is the objective and will enable NWBO's
manufacturing partners to meet the expected high demand once approved.
The good news is that the recent trial information supports DCVax-L data results of 50% to 55% with 100+ months of extended survival rate, IMPO. This is far better than the flux capacitor helmet by a factor of 4X to 5X, WOW, IMPO.